Carol MacGregor

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials

Ignace Vergote, Corneel Coens, Matthew Nankivell et al. · The Lancet Oncology · 2018 · 306 citations · Full text

Medicine, Oncology, Surgery +13

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 283 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

Dean A. Fennell, Sean Ewings, Christian H. Ottensmeier et al. · The Lancet Oncology · 2021 · 259 citations · Full text

Medicine, Oncology, Pharmacology +15

Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer

Peter Hoskin, Kirsten Hopkins, Vivek Misra et al. · JAMA · 2019 · 118 citations · Full text

Medicine, Oncology, Radiation Oncology +16

A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer

Carol MacGregor, Peter Canney, G. A. Patterson et al. · European Journal of Cancer · 2005 · 110 citations

Medicine, Gynecology, Oncology +13